CHMA News and Press, Chiasma Inc. From 07/01/20

Chiasma sinks ( CHMA -16.3% ) after pricing  its previously announced public offering of 12.5M shares at $4/share. More news on: Chiasma, Inc., Healthcare stocks news, , Read more ...

NEEDHAM, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platform technology to reduce the bu...

Polar Power (NASDAQ: POLA ) -19% . More news on: Polar Power, Inc., Apex Global Brands Inc., CPS Technologies Corporation, Stocks on the move, , Read more ...

Gainers:  AKRO +33.8% . ETNB +21.1% . FDX +8.9% . AKCA +5.8% . UPS +5.0% . More news on: Akero Therapeutics, Inc., 89bio, Inc., FedEx Corporation, Stocks on the move, , Read more ...

Chiasma (NASDAQ: CHMA ) slides  6.9%  during AH, as the company announces  an underwritten public offering of shares, and pre-funded warrants. Underwriters have an option to purchase up to an additional 15% shares and pre-funded warrants sold. More news on: Chiasma, Inc., H...

NEEDHAM, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platform technology to reduce the bu...

NOTE: MM = million Our analysis concludes Chiasma, Inc.'s (CHMA) share price is materially undervalued primarily because, at $6/share or ~$300 million market cap, CHMA trades at only slightly more than estimated peak annual revenues (just in the United States, completely excluding the rest o...

Acceleron Reports Positive Top-Line Results for PULSAR Trial Acceleron Pharma, Inc. (XLRN) announced top-line results from its Phase 2 trial testing sotatercept in patients with pulmonary arterial hypertension. The trial involved 106 patients who were randomized to be administered placebo,...

The FDA approves Chiasma's ( CHMA -1.5% ) Mycapssa (octreotide) for the long-term maintenance treatment of adult patients with acromegaly , a disorder in which the pituitary gland produces excessive amounts of growth hormone which causes bones in the hands, feet and face to increase in ...

MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide Conference call and webcast scheduled today at 2 pm ET NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. ...